{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:02:42Z","timestamp":1789779762982,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peptide receptor radionuclide therapy (PRRT) with \u00b9\u2077\u2077Lu-DOTATATE improves outcomes in neuroendocrine tumors (NETs), yet durable disease control remains limited in progressive pancreatic NET (pNET) and higher-grade disease. Combinations that enhance PRRT efficacy may be advantageous. As sunitinib has radiosensitizing and immunomodulatory effects, we explored the clinical activity and mechanistic basis of combining sunitinib with PRRT. Combination treatment with \u00b9\u2077\u2077Lu-DOTATATE (1\u20133 cycles; 7.4 GBq per cycle) and sunitinib at 37.5\u2009mg\/day was well tolerated and effective in a pilot group of heavily pretreated pNET patients with progressive disease. Treatment response was assessed by \u2076\u2078Ga-DOTATOC PET\/CT and serum tumor markers (CgA, NSE). Mechanistic studies were performed in QGP-1 pNET cells using proliferation and apoptosis assays, cell-cycle analysis, and immunogenic cell death (ICD) markers. Combination therapy was well tolerated and induced marked responses: three patients achieved near-complete responses and two partial responses on post-therapy \u2076\u2078Ga-DOTATOC PET\/CT. In vitro, \u00b9\u2077\u2077Lu-DOTATATE and sunitinib showed bidirectional sensitization: low-dose sunitinib reduced the LD50 of \u00b9\u2077\u2077Lu-DOTATATE, and low-activity \u00b9\u2077\u2077Lu-DOTATATE reduced the LD50 of sunitinib. \u00b9\u2077\u2077Lu-DOTATATE induced dose-dependent PARP cleavage and S\/G2\u2013M arrest; however, sunitinib shifted cell death toward late apoptosis\/necrosis. The combination produced a more-than-additive increase in calreticulin exposure on the tumor cell surface and enhanced HMGB1 but not interleukin- 1\u00df- or interleukin-18-release compared with either monotherapy, indicating immunogenic late apoptosis\/necrosis, without canonical inflammasome activation. Intermittent sunitinib combined with \u00b9\u2077\u2077Lu-DOTATATE PRRT demonstrated encouraging activity in progressive pNET. The mechanism of synergy in vitro was enhanced ICD, suggesting that immune responses contribute to the synergy in vivo.<\/jats:p>","DOI":"10.1038\/s41420-026-03344-z","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:53:32Z","timestamp":1789775612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenic cell death as a mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1884-1944","authenticated-orcid":false,"given":"Markus","family":"Essler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Veit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milka","family":"Marinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kreppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"3344_CR1","doi-asserted-by":"publisher","first-page":"2569992","DOI":"10.1080\/07853890.2025.2569992","volume":"57","author":"L Mastnak","year":"2025","unstructured":"Mastnak L, Badovinac D. From diagnosis to treatment: navigating the course for pancreatic neuroendocrine neoplasms. Ann Med. 2025;57:2569992.","journal-title":"Ann Med"},{"key":"3344_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0780","volume":"86","author":"DM Pritchard","year":"2025","unstructured":"Pritchard DM. Neuroendocrine tumours in the gastrointestinal tract: what you need to know. Br J Hosp Med (Lond). 2025;86:1\u201313.","journal-title":"Br J Hosp Med (Lond)"},{"key":"3344_CR3","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656\u201363.","journal-title":"J Clin Oncol"},{"key":"3344_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, Phan AT, Raderer M, Sedl\u00e1\u010dkov\u00e1 E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224\u201333.","journal-title":"N Engl J Med"},{"key":"3344_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514\u201323.","journal-title":"N Engl J Med"},{"key":"3344_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501\u201313.","journal-title":"N Engl J Med"},{"key":"3344_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa2403991","volume":"392","author":"JA Chan","year":"2025","unstructured":"Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, et al. Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. N Engl J Med. 2025;392:653\u201365.","journal-title":"N Engl J Med"},{"key":"3344_CR8","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/jcm8091474","volume":"8","author":"RA Bundschuh","year":"2019","unstructured":"Bundschuh RA, Habacha B, L\u00fctje S, Essler M. Therapy of patients with neuroendocrine neoplasia-evidence-based approaches and new horizons. J Clin Med. 2019;8:1474.","journal-title":"J Clin Med"},{"key":"3344_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"3344_CR10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00259-019-04499-x","volume":"47","author":"S Adant","year":"2020","unstructured":"Adant S, Shah GM, Beauregard JM. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2020;47:907\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3344_CR11","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1097\/RLU.0000000000002532","volume":"44","author":"A Yordanova","year":"2019","unstructured":"Yordanova A, Ahrens H, Feldmann G, Brossart P, Gaertner FC, Fottner C, et al. Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors. Clin Nucl Med. 2019;44:e329\u201335.","journal-title":"Clin Nucl Med"},{"key":"3344_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1491475","volume":"2020","author":"K Mayer","year":"2020","unstructured":"Mayer K, Kiry S, Yordanova A, Ahmadzadehfar H, Gaertner FC, Bundschuh RA, et al. Systemic therapy of neuroendocrine neoplasia: single center experience from a cohort of 110 consecutive cases. Int J Endocrinol. 2020;2020:1491475.","journal-title":"Int J Endocrinol"},{"key":"3344_CR13","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1007\/s00259-021-05236-z","volume":"48","author":"S Nicolini","year":"2021","unstructured":"Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, et al. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2021;48:3260\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3344_CR14","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1097\/RLU.0000000000005018","volume":"49","author":"P Aggarwal","year":"2023","unstructured":"Aggarwal P, Gunasekaran V, Sood A, Gupta K, Das CK, Mittal BR. Sunitinib in tandem with 177Lu-DOTATATE therapy in advanced pancreatic neuroendocrine tumor: a new treatment approach. Clin Nucl Med. 2023;49:e85\u2013e86.","journal-title":"Clin Nucl Med"},{"key":"3344_CR15","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1158\/1078-0432.CCR-18-0947","volume":"24","author":"A Yordanova","year":"2018","unstructured":"Yordanova A, Wicharz MM, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, et al. The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy. Clin Cancer Res. 2018;24:4672\u20139.","journal-title":"Clin Cancer Res"},{"key":"3344_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11912-024-01521-w","volume":"26","author":"DS Hoogenkamp","year":"2024","unstructured":"Hoogenkamp DS, de Wit-van der Veen LJ, Huizing DMV, Tesselaar MET, van Leeuwaarde RS, Stokkel MPM, et al. Advances in radionuclide therapies for patients with neuro-endocrine tumors. Curr Oncol Rep. 2024;26:551\u201361.","journal-title":"Curr Oncol Rep"},{"key":"3344_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fonc.2013.00113","volume":"3","author":"E Mladenov","year":"2013","unstructured":"Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol. 2013;3:113.","journal-title":"Front Oncol"},{"key":"3344_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/HP.0000000000001601","volume":"123","author":"Y Jiao","year":"2022","unstructured":"Jiao Y, Cao F, Liu H. Radiation-induced cell death and its mechanisms. Health Phys. 2022;123:376\u201386.","journal-title":"Health Phys"},{"key":"3344_CR19","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1016\/j.molcel.2025.09.007","volume":"85","author":"R Chen","year":"2025","unstructured":"Chen R, Zou J, Liu J, Kang R, Tang D. DAMPs in the immunogenicity of cell death. Mol Cell. 2025;85:3874\u201389.","journal-title":"Mol Cell"},{"key":"3344_CR20","doi-asserted-by":"publisher","first-page":"63ra94","DOI":"10.1126\/scitranslmed.3001375","volume":"2","author":"MP Chao","year":"2010","unstructured":"Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2:63ra94.","journal-title":"Sci Transl Med"},{"key":"3344_CR21","doi-asserted-by":"publisher","first-page":"956","DOI":"10.2967\/jnumed.120.245290","volume":"62","author":"DY Kim","year":"2021","unstructured":"Kim DY, Pyo A, Yun M, Thangam R, You SH, Zhang Y, et al. Imaging calreticulin for early detection of immunogenic cell death during anticancer treatment. J Nucl Med. 2021;62:956\u201360.","journal-title":"J Nucl Med"},{"key":"3344_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fimmu.2013.00068","volume":"4","author":"G Li","year":"2013","unstructured":"Li G, Liang X, Lotze MT. HMGB1: the central cytokine for all lymphoid cells. Front Immunol. 2013;4:68.","journal-title":"Front Immunol"},{"key":"3344_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705361","volume":"12","author":"M Zhu","year":"2021","unstructured":"Zhu M, Yang M, Zhang J, Yin Y, Fan X, Zhang Y, et al. Immunogenic cell death induction by ionizing radiation. Front Immunol. 2021;12:705361.","journal-title":"Front Immunol"},{"key":"3344_CR24","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.7150\/ijms.109515","volume":"22","author":"ZS Hang","year":"2025","unstructured":"Hang ZS, Huang YY, Song A, Sun ZJ. Radiotherapy elicits immunogenic cell death and metabolic shifts in the tumor microenvironment: implications for immunotherapy. Int J Med Sci. 2025;22:3277\u201391.","journal-title":"Int J Med Sci"},{"key":"3344_CR25","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.3390\/cancers12113448","volume":"12","author":"A Busse","year":"2020","unstructured":"Busse A, Mochmann LH, Spenke C, Arsenic R, Briest F, J\u00f6hrens K, et al. Immunoprofiling in neuroendocrine neoplasms unveil immunosuppressive microenvironment. Cancers (Basel). 2020;12:3448.","journal-title":"Cancers (Basel)"},{"key":"3344_CR26","doi-asserted-by":"publisher","unstructured":"Kreppel B, Fink J, Sanders C, Scherping A, Hommerding O, Marinova M, et al. Prognostic significance of CD68+ macrophages and FoxP3+ regulatory T cells in neuroendocrine tumors. nuklearmedizin. (2025). https:\/\/doi.org\/10.1055\/a-2739-5187.","DOI":"10.1055\/a-2739-5187"},{"key":"3344_CR27","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-25-0052","volume":"32","author":"AR Siebenh\u00fcner","year":"2025","unstructured":"Siebenh\u00fcner AR, Refardt J, Nicolas GP, Kaderli R, Walter MA, Perren A, et al. Impact of multikinase inhibitors in reshaping the treatment of advanced gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2025;32:e250052.","journal-title":"Endocr Relat Cancer"},{"key":"3344_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.577766","volume":"12","author":"D Ocadlikova","year":"2021","unstructured":"Ocadlikova D, Lecciso M, Broto JM, Scotlandi K, Cavo M, Curti A, et al. Sunitinib exerts in vitro immunomodulatory activity on sarcomas via dendritic cells and synergizes with PD-1 blockade. Front Immunol. 2021;12:577766.","journal-title":"Front Immunol"},{"key":"3344_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106227","volume":"81","author":"W Li","year":"2020","unstructured":"Li W, Zhan M, Quan YY, Wang H, Hua SN, Li Y, et al. Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy. Int Immunopharmacol. 2020;81:106227.","journal-title":"Int Immunopharmacol"},{"key":"3344_CR30","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.3390\/ijms232012369","volume":"23","author":"W Delbart","year":"2022","unstructured":"Delbart W, Karabet J, Marin G, Penninckx S, Derrien J, Ghanem GE, et al. Understanding the radiobiological mechanisms induced by 177Lu-DOTATATE in comparison to external beam radiation therapy. Int J Mol Sci. 2022;23:12369.","journal-title":"Int J Mol Sci"},{"key":"3344_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.755433","volume":"11","author":"F Scirocchi","year":"2021","unstructured":"Scirocchi F, Napoletano C, Pace A, Rahimi Koshkaki H, Di Filippo A, Zizzari IG, et al. Immunogenic cell death and immunomodulatory effects of cabozantinib. Front Oncol. 2021;11:755433.","journal-title":"Front Oncol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03344-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03344-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03344-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:15:39Z","timestamp":1789776939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03344-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3344"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03344-z","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee at the Medical Faculty of the University of Bonn (338\/23-EP). Written informed consent was obtained from all patients.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"379"}}